Global Blood Cancer Market Forecast to 2028
The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand-new report you will receive 61 charts – all unavailable elsewhere.
This report provides clear detailed insight into the global blood cancer market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Revenue and growth forecasts to 2028 for the blood cancer market
- Revenue and growth forecast to 2028 for the blood cancer market by type of therapy:
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Revenue and growth forecast to 2028 for the blood cancer market by regional and national market:
- The US
- Japan
- Germany
- France
- The UK
- Spain
- Italy
- Brazil
- Russia
- India
- China
- For each national market, this report provides incident cases projection from 2018 to 2028 for:
- Leukaemia
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Multiple Myeloma
- Discussion and profiles of the leading players in the blood cancer market:
- Amgen
- AstraZeneca
- Bayer
- Bristol-Myers Squibb (BMS)
- Celgene
- Johnson & Johnson
- Novartis
- Pfizer
- Roche
- Discussion on drugs that are currently in the R&D pipeline for Leukaemia, Lymphoma and Multiple Myeloma.
- Analysis of what stimulates and restrains the global blood cancer market: Porter’s Five Forces Analysis, Trends, Drivers and Challenges
- Key Questions Answered by this Report:
- How is the Blood Cancer market evolving?
- What are the drivers and restraints for the growth of the Blood Cancer market?
- How will each Blood Cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2028?
- What will be the main driver for the overall market to 2028?
- How will political and regulatory factors influence the regional markets and submarkets?
- Will leading national Blood Cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?
- Who are the leading players and what are their prospects over the forecast period?
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Global Blood Cancer Market Overview
- 1.2 Why You Should Read This Report
- 1.3 How This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 How This Report Delivers
- 1.6 Key Questions Answered by This Analytical Report
- 1.7 Who is This Report For?
- 1.8 Methodology
- 1.8.1 Primary Research
- 1.8.2 Secondary Research
- 1.8.3 Market Evaluation & Forecasting Methodology
- 1.9 Frequently Asked Questions (FAQ)
- 1.10 Associated Visiongain Reports
- 1.11 About Visiongain
- 2. The Global Blood Cancer Market by Therapy Area: Incident Cases by Country 2018-2018
- 2.1 Overview of Blood Cancer
- 2.2 Signs and Symptoms
- 2.3 Causes of Blood Cancer
- 2.4 Blood Cancer Treatment & Therapy Options
- 2.5 Leukaemia
- 2.5.1 Acute Lymphocytic Leukaemia (ALL) in Adults
- 2.5.2 Acute Myeloid Leukaemia (AML)
- 2.5.3 Chronic Lymphocytic Leukaemia (CLL)
- 2.5.4 Chronic Myeloid Leukaemia (CML)
- 2.5.5 Chronic Myelomonocytic Leukaemia
- 2.5.6 Leukaemia in Children
- 2.5.7 Survival
- 2.6 Lymphoma
- 2.6.1 Non-Hodgkin lymphomas
- 2.6.2 Hodgkin disease
- 2.6.3 Survival
- 2.7 Myeloma
- 2.7.1 Survival
- 3. The Global Blood Cancer Market by Type of Therapy: Market Forecast to 2028
- 3.1 An Introduction to Various Types of Therapies
- 3.2 Chemotherapy
- 3.2.1 Global Chemotherapy Market Forecast to 2028
- 3.3.1 Global Targeted Therapy Market Forecast to 2028
- 3.4 Immunotherapy
- 3.4.1 Global Immunotherapy Market Forecast to 2028
- 4. Global Blood Cancer Market by Region: Market Forecast to 2028
- 4.1 An Introduction to the Market Geography
- 4.2 United States Blood Cancer Market Forecast to 2028
- 4.2.1 United States Blood Cancer Market by Disease Type
- 4.2.2 United States Blood Cancer Market by Type of Therapy: Forecast to 2028
- 4.3 EU5 Blood Cancer Market Forecast to 2028
- 4.3.1 EU5 Blood Cancer Market by Disease Type
- 4.3.2 EU5 Blood Cancer Market Forecast by Type of Therapy: Forecast to 2028
- 4.3.3 EU5 Blood Cancer Market by Country Share, 2018 and 2028
- 4.4 BRIC Blood Cancer Market Forecast to 2028
- 4.4.1 BRIC Blood Cancer Market by Disease Type
- 4.4.2 BRIC Blood Cancer Market by Type of Therapy: Forecast to 2028
- 4.4.3 BRIC Countries Blood Cancer Market
- 4.4.3.1 Brazil
- 4.4.3.2 India
- 4.4.3.3 Russia
- 4.4.3.4 China
- 4.4 Japan Blood Cancer Market Forecast to 2028
- 4.4.1 Japan Blood Cancer Market: by Disease Type
- 4.4.2 Japan Blood Cancer Market by Type of Therapy: Forecast to 2028
- 5. Leading Companies in the Blood Cancer Market
- 5.1 Introduction
- 5.1.1 Amgen Inc.
- 5.1.1.1 Business Overview
- 5.1.1.2 Recent Financials
- 5.1.1.3 Product Offerings
- 5.1.1.4 Recent developments
- 5.1.2 AstraZeneca PLC
- 5.1.2.1 Business Overview
- 5.1.2.2 Recent Financials
- 5.1.2.3 Product Offerings
- 5.1.2.4 Recent developments
- 5.1.3 Bayer AG
- 5.1.3.1 Business Overview
- 5.1.3.2 Recent Financials
- 5.1.3.3 Product Offerings
- 5.1.3.4 Recent developments
- 5.1.4 Bristol-Myers Squibb Company
- 5.1.4.1 Business Overview
- 5.1.4.2 Recent Financials
- 5.1.4.3 Product Offerings
- 5.1.4.4 Recent developments
- 5.1.5 Celgene Corporation
- 5.1.5.1 Business Overview
- 5.1.5.2 Recent Financials
- 5.1.5.3 Product Offerings
- 5.1.5.4 Recent developments
- 5.1.6 Roche
- 5.1.6.1 Business Overview
- 5.1.6.2 Recent Financials
- 5.1.6.3 Product Offerings
- 5.1.6.4 Recent developments
- 5.1.7 Johnson & Johnson
- 5.1.7.1 Business Overview
- 5.1.7.2 Recent Financials
- 5.1.8 Novartis
- 5.1.8.1 Business Overview
- 5.1.8.2 Recent Financials
- 5.1.8.3 Product Offerings
- 5.1.8.4 Recent developments
- 5.1.9 Pfizer Inc.
- 5.1.9.1 Business Overview
- 5.1.9.2 Recent Financials
- 5.1.9.3 Product Offerings
- 5.1.9.4 Recent Developments
- 6. Blood Cancer: R&D Pipeline
- 6.1 Blood Cancer: R&D Pipeline
- 6.1.1 Drugs for Leukemia
- 6.1.2 Drugs for Lymphoma
- 6.1.3 Multiple Myeloma
- 6.1.4 Other Major Drugs Under Different Stages of Development
- 7. Qualitative Analysis
- 7.1. Porter’s Five Forces Analysis
- 7.1.1. Bargaining power of buyers (MEDIUM)
- 7.1.2 Bargaining power of suppliers (LOW)
- 7.1.3 Industry rivalry (HIGH)
- 7.1.4 Threat of new entrants
- 7.1.5 Threat of substitutes (HIGH)
- 7.2 Market Dynamics of Blood Cancer Market
- 7.2.1 Trends
- 7.2.2 Drivers
- 7.2.3 Challenges
- 8. Conclusions & Recommendations
- 8.1 Key Takeaway
- 8.2 Conclusion
- Appendices
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain Report Evaluation Form
- List of Tables
- Table 2.1 Incident Cases of Leukaemia by Country: 2018-2028
- Table 2.2 Incident cases of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
- Table 2.3 Incident Cases of Hodgkin Lymphoma (HL) by Country: 2018-2028
- Table 2.4 Incident cases of Multiple Myeloma by Country: 2018-2028
- Table 3.1 Global Blood Cancer Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2028
- Table 3.2 Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CARG (%), 2018-2028
- Table 3.3 Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
- Table 3.4 Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.1 United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.2 Incident Cases of Different Types of Cancers in the US: 2018-2028
- Table 4.3: United States Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.4 EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.5 Incident Cases of Different Types of Cancers in the EU5
- Table 4.6 EU5 Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.7 BRIC Blood Cancer Market Forecast 2018-2028 by Country: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.8 Incident Cases of Different Types of Cancers in BRIC Countries: 2018-2028
- Table 4.9 BRIC Countries Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
- Table 4.10 Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%), CAGR (%)
- Table 4.11 Incident Cases of Different Types of Cancers in Japan: 2018-2028
- Table 4.12 Japan Blood Cancer Market Forecast by Type of Therapy: Revenue ($bn), 2018-2028
- Table 5.1 Amgen Inc.: Key Facts
- Table 5.2 Amgen Inc.: Financial Information 2016-2017
- Table 5.3 AstraZeneca PLC: Key Facts
- Table 5.4 AstraZeneca PLC: Financial Information 2016-2017
- Table 5.5 Bayer AG: Key Facts
- Table 5.6 Bayer AG: Recent Financials 2016-2017
- Table 5.7 Bristol-Myers Squibb Company – Key Facts
- Table 5.8 Bristol-Myers Squibb: Recent Financials 2016-2017
- Table 5.9 Celgene Corporation: Key Facts
- Table 5.10 Celgene: Recent Financials 2016-2017
- Table 5.11 Roche: Key Facts
- Table 5.12 Roche: Recent Financials 2016-2017
- Table 5.13 Johnson & Johnson: Key Facts
- Table 5.14 Johnson & Johnson: Recent Financials 2016-2017
- Table 5.15 Novartis AG: Key Facts
- Table 5.16 Novartis: Recent Financials 2016-2017
- Table 5.17 Pfizer Inc.: Key Facts
- Table 5.18 Pfizer Inc.: Recent Financials 2016-2017
- Table 6.1 Major Drugs Udder Development
- List of Figures
- Figure 2.1 Types of Blood Cancer
- Figure 2.2 Different Types of Leukaemia
- Figure 2.3 Trend of Leukaemia Cases by Country: 2018-2028
- Figure 2.4 Trend of Non-Hodgkin Lymphoma (NHL) by Country: 2018-2028
- Graph 2.5 Trend of Hodgkin Lymphoma (NHL) by Country: 2018-2028
- Figure 2.6 Trend of Multiple Myeloma by Country: 2018-2028
- Figure 3.1 Market Size of Cancer Therapy by Type ($bn): 2018-2028
- Figure 3.2 Market share (%) of Cancer Therapy by Type: 2018 and 2028
- Figure 3.3: Global Chemotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 3.4 Global Targeted Therapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 3.5 Global Immunotherapy Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 4.1 Blood Cancer Market by Region: % Share, 2018
- Figure 4.2 Blood Cancer Market by Region: % Share, 2028
- Figure 4.3: United States Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 4.4: Distribution of Different Types of Blood Cancer in the US: 2018-2028
- Figure 4.5: EU5 Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 4.6 EU5 Blood Cancer Market by Country: % Share, 2018 and 2028
- Figure 4.7: BRIC Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 4.8: Japan Blood Cancer Market Forecast 2018-2028: Revenue ($bn), AGR (%)
- Figure 4.9: Distribution of Different Types of Blood Cancer in Japan: 2018-2028
- Figure 8.1: Global Blood Cancer Market by Region: Revenue ($bn), 2018
- Figure 8.2: Global Blood Cancer Market by Region: Revenue ($bn), 2018
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook